Biofeedback vagal nerve stimulating breathing reduced HOSTILITY and reduced hospitalizations by 50% and ER visits by 65%.
Two minutes of slow 0.1cps breathing twice daily improves costs, mood and outcome in CAD patients. Actually this is useful for everyone with metabolic syndrome, provides a free smoking cessation benefit from acetylcholine blocking of the alpha 7 Nicotinic acetylcholine receptor, the same receptor that chantix occupies.
This is a free treatment with infinite return on investment.
Combined with Tabata four minutes of daily high intensity interval exercise it promotes healthy functional ANS autonomic tone in 8 minutes daily. Autonomic dysfunction, either too much sympathetic or too much vagal tone results in damaging dysautonomia.
This is practical low hanging fruit to improve our outcomes. Vagal tone activates the cholinergic anti inflammatory pathway and likely protects all organs and not just the heart.
Exercise and mindfulness, improved autonomic tone and function, improves anxiety and depression by 42% or results in RESILIENCE.
Shouldn't this be part of CCM? Shouldn't this be part of wellness for the 62% of our insulin resistance patients at increased risk for cardiovascular morbidity?
Couldn't this reduce health insurance costs for state teachers and employees?. Small no cost change in big populations produces large benefits and savings which compound year over year.
One-Year Cardiovascular Prognosis of the Randomized, Controlled, Short-Term Heart Rate Variability Biofeedback Among Patients with Coronary Artery Disease
Abstract
Purpose
Heart rate variability biofeedback (HRV-BF) is an effective psychophysiological intervention, with short-term effects of increased autonomic nervous system homeostasis, strengthened baroreflex sensitivity, and decreased hostility in patients with coronary artery disease (CAD). The study examined the 1-year HRV-BF effect on cardiovascular prognosis of these patients.
Methods
Of 222 patients with CAD referred by cardiologists, 210 were screened and randomly assigned to the HRV-BF and control groups. All patients received psychophysiological assessment and completed psychological questionnaires at pre- and post-interventions and 1-year follow-up. The cardiovascular prognosis primary endpoints included hospital readmission, emergency revisits, and mortality.
Results
The HRV-BF group had fewer all-cause readmissions (12.00 vs. 25.42%) and all-cause emergency visits (13.33 vs. 35.59%) than the control group. The low-frequency HRV in the HRV-BF group increased at post-intervention and 1-year follow-up compared with that at pre-intervention. Although no significant interaction effect was found in the standard deviation of the normal-to-normal intervals (F = 2.96, p = 0.055), it increased by 26.68% from pre- to post-intervention and 15.77% from pre-intervention to follow-up in the HRV-BF group. However, it decreased by 3.60% from pre- to post-intervention and increased by 1.99% from pre-intervention to follow-up in the control group. Depression and hostility scores decreased significantly at post-intervention and 1-year follow-up only in the HRV-BF group.
Conclusions
The long-term HRV-BF effect was confirmed by improved cardiovascular prognosis, increased cardiac autonomic homeostasis and baroreflex sensitivity, and decreased depression and hostility. HRV-BF is an effective psychophysiological intervention with short- and long-term effects in cardiac rehabilitation programs.
Joseph Thomas (Tony) Liverman, Jr.
No comments:
Post a Comment